Literature DB >> 20422274

Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis?

Elena Bargagli1, Carmela Olivieri, Marcella Cintorino, Rosa M Refini, Nicola Bianchi, Antje Prasse, Paola Rottoli.   

Abstract

Calgranulin B is a small calcium-binding protein with several immunological functions mainly involved in chronic inflammation and cancer. It can participate in recruitment of neutrophils and leukocytes in inflamed tissue, oxidant/antioxidant balance, adhesion of neutrophils to fibronectin, and regulation of apoptosis. In a previous proteomic study, we found that calgranulin B was up-regulated in the bronchoalveolar lavage (BAL) of patients with idiopathic pulmonary fibrosis (IPF) with respect to controls and patients with other interstitial lung diseases. The aims of this study are to compare calgranulin B concentrations in BAL of patients with IPF and sarcoidosis and controls by a quantitative method, to look for correlations with clinical data, and to evaluate calgranulin B expression in lung tissue of IPF patients by immunohistochemistry. A modification of a commercial ELISA was used to determine calgranulin B concentrations in BAL of 16 patients with IPF (a group of patients in which we previously performed proteomic analysis), 17 patients with sarcoidosis, and 7 controls. The immunohistochemistry was done in a subgroup of patients with IPF and a control group of lung transplant donors. Calgranulin B concentrations were significantly higher in patients with IPF than controls (p < 0.01); they were inversely correlated with FVC and DLCO values and directly correlated with neutrophil and eosinophil percentages in BAL. Immunohistochemistry revealed a patchy distribution of calgranulin B, predominantly around areas of fibrotic remodeling. Calgranulin B may be a trigger molecule involved in the evolution and progression of IPF, being overexpressed in BAL of patients with IPF with severe functional deterioration and in the peribronchiolar area bordering zones of honeycombing.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20422274     DOI: 10.1007/s10753-010-9210-7

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  40 in total

1.  Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis.

Authors:  M W Ziegenhagen; M E Rothe; M Schlaak; J Müller-Quernheim
Journal:  Eur Respir J       Date:  2003-03       Impact factor: 16.671

Review 2.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

Review 3.  S100A8 and S100A9 in inflammation and cancer.

Authors:  Christoffer Gebhardt; Julia Németh; Peter Angel; Jochen Hess
Journal:  Biochem Pharmacol       Date:  2006-07-17       Impact factor: 5.858

4.  Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias.

Authors:  K Kuwano; N Nakashima; I Inoshima; N Hagimoto; M Fujita; M Yoshimi; T Maeyama; N Hamada; K Watanabe; N Hara
Journal:  Eur Respir J       Date:  2003-02       Impact factor: 16.671

5.  Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity.

Authors:  H J Haga; J G Brun; H B Berntzen; R Cervera; M Khamashta; G R Hughes
Journal:  Lupus       Date:  1993-02       Impact factor: 2.911

6.  The role of the receptor for advanced glycation end-products in lung fibrosis.

Authors:  Mei He; Hiroshi Kubo; Kota Ishizawa; Ahmed E Hegab; Yasuhiko Yamamoto; Hiroshi Yamamoto; Mutsuo Yamaya
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-10-19       Impact factor: 5.464

7.  Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases.

Authors:  Eva Lorenz; Marianne S Muhlebach; Philippe A Tessier; Neil E Alexis; R Duncan Hite; Michael C Seeds; David B Peden; Wayne Meredith
Journal:  Respir Med       Date:  2007-12-27       Impact factor: 3.415

8.  Outcome of the treatment for sarcoidosis.

Authors:  G W Hunninghake; S Gilbert; R Pueringer; C Dayton; C Floerchinger; R Helmers; R Merchant; J Wilson; J Galvin; D Schwartz
Journal:  Am J Respir Crit Care Med       Date:  1994-04       Impact factor: 21.405

9.  BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia.

Authors:  S Veeraraghavan; P I Latsi; A U Wells; P Pantelidis; A G Nicholson; T V Colby; P L Haslam; E A Renzoni; R M du Bois
Journal:  Eur Respir J       Date:  2003-08       Impact factor: 16.671

10.  Subunit structure of calgranulins A and B obtained from sputum, plasma, granulocytes and cultured epithelial cells.

Authors:  D Longbottom; J M Sallenave; V van Heyningen
Journal:  Biochim Biophys Acta       Date:  1992-04-08
View more
  13 in total

1.  Pro-inflammatory S100A9 Protein: a Double-Edged Sword in Cancer?

Authors:  Vahid Bagheri; Vasso Apostolopoulos
Journal:  Inflammation       Date:  2019-08       Impact factor: 4.092

2.  Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.

Authors:  Andrea L Martinez-Skinner; Ram S Veerubhotla; Han Liu; Huangui Xiong; Fang Yu; JoEllyn M McMillan; Howard E Gendelman
Journal:  J Proteome Res       Date:  2013-04-17       Impact factor: 4.466

3.  Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience.

Authors:  David Bennett; Antonella Fossi; Elena Bargagli; Rosa Metella Refini; Maria Pieroni; Luca Luzzi; Claudia Ghiribelli; Piero Paladini; Luca Voltolini; Paola Rottoli
Journal:  Lung       Date:  2015-07-28       Impact factor: 2.584

4.  S100A9 promotes human lung fibroblast cells activation through receptor for advanced glycation end-product-mediated extracellular-regulated kinase 1/2, mitogen-activated protein-kinase and nuclear factor-κB-dependent pathways.

Authors:  X Xu; H Chen; X Zhu; Y Ma; Q Liu; Y Xue; H Chu; W Wu; J Wang; H Zou
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

5.  The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.

Authors:  Kota Araki; Rie Kinoshita; Nahoko Tomonobu; Yuma Gohara; Shuta Tomida; Yuta Takahashi; Satoru Senoo; Akihiko Taniguchi; Junko Itano; Ken-Ichi Yamamoto; Hitoshi Murata; Ken Suzawa; Kazuhiko Shien; Hiromasa Yamamoto; Mikio Okazaki; Seiichiro Sugimoto; Kouichi Ichimura; Masahiro Nishibori; Nobuaki Miyahara; Shinichi Toyooka; Masakiyo Sakaguchi
Journal:  J Mol Med (Berl)       Date:  2020-11-09       Impact factor: 4.599

6.  Macrophage-derived biomarkers of idiopathic pulmonary fibrosis.

Authors:  E Bargagli; A Prasse; C Olivieri; J Muller-Quernheim; P Rottoli
Journal:  Pulm Med       Date:  2010-11-29

7.  Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators.

Authors:  Rim Serhal; George Hilal; George Boutros; Joseph Sidaoui; Layal Wardi; Salah Ezzeddine; Nada Alaaeddine
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

8.  Migratory phase of Litomosoides sigmodontis filarial infective larvae is associated with pathology and transient increase of S100A9 expressing neutrophils in the lung.

Authors:  Gregory Karadjian; Frédéric Fercoq; Nicolas Pionnier; Nathaly Vallarino-Lhermitte; Emilie Lefoulon; Adélaïde Nieguitsila; Sabine Specht; Leo M Carlin; Coralie Martin
Journal:  PLoS Negl Trop Dis       Date:  2017-05-09

9.  Sarcospan: a small protein with large potential for Duchenne muscular dystrophy.

Authors:  Jamie L Marshall; Rachelle H Crosbie-Watson
Journal:  Skelet Muscle       Date:  2013-01-03       Impact factor: 4.912

Review 10.  The perplexing role of RAGE in pulmonary fibrosis: causality or casualty?

Authors:  Timothy N Perkins; Tim D Oury
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.